Silicon Canals
TRENDING
  • Mobility
  • AI
  • FinTech
  • Software & SaaS
No Result
View All Result
  • Home
  • News
    • Ukraine
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
    • COVID-19
  • Features
    • How-to
    • Knowledge & Insights
    • Guest Contributions
  • Partners
    • Amsterdam
    • Rise by Techleap.nl
    • Fintech Files by AWS
    • Scaling-up in Europe
    • Blue Tulip Awards
    • Partner with us
    • Promoted content
  • Jobs
  • About us
    • Partner with us
    • About
    • Team
    • Newsletter
  • Contact
  • Home
  • News
    • Ukraine
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
    • COVID-19
  • Features
    • How-to
    • Knowledge & Insights
    • Guest Contributions
  • Partners
    • Amsterdam
    • Rise by Techleap.nl
    • Fintech Files by AWS
    • Scaling-up in Europe
    • Blue Tulip Awards
    • Partner with us
    • Promoted content
  • Jobs
  • About us
    • Partner with us
    • About
    • Team
    • Newsletter
  • Contact
No Result
View All Result
Silicon Canals
No Result
View All Result
This article is produced in collaboration with our partner StartupAmsterdam

Amsterdam-based NorthSea Therapeutics secures €70.84M to develop treatment for metabolic disorders

Vishal Singh by Vishal Singh
December 21, 2021
in (Crowd)funding, Amsterdam, News, Promoted content
NorthSea Therapeutics

NorthSea Therapeutics' CEO Rob de Ree | Image credit: NorthSea Therapeutics

26
SHARES
LinkedInTwitterWhatsAppFacebook

Amsterdam-based NorthSea Therapeutics (NST), a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics, announced that it has raised $80M (approx €70.84M) in its Series C round of funding.

Rob de Ree, NST’s CEO, says, “We are delighted to close this Series C financing, further building our strong investor syndicate with new premium funds, and with the continued support of existing investors. The fundraise will support us in taking the next steps across our clinical development pipeline, enabling NST to grow into a multi-asset company in clinical and  late-clinical stage.” 

- Partner content -
EIT Digital
EIT Digital Challenge 2022 is here!
Calling all European deep-tech scaleups for EIT Digital Challenge 2022Show More
Calling all European deep-tech scaleups for EIT Digital Challenge 2022 Show Less
Read more

Investors in this round

The round was co-led by Ysios Capital and Forbion Growth. New investors including a large managed care organisation and Hercules Capital, and existing investors Forbion Ventures, venBio, Novo Seeds, Sofinnova, BGV, and New Science Ventures also participated in the round.

With this investment, Jordi Xiol, Principal at Ysios Capital and Dirk Kersten, General Partner at Forbion Growth, will join NST’s board of directors.

Jordi Xiol says, “The widespread medical need presented by non-alcoholic steatohepatitis (NASH) remains largely unmet and we believe that a successful treatment will have to address patients’ conditions as a whole. Icosabutate is a safe, oral molecule, which has shown strong anti-inflammatory properties for the liver, while also improving metabolic disorder. We are  enthusiastic to support NST’s strong team in the development of a pipeline centred around the  production of SEFAs.”

Capital utilisation

The proceeds from this round will be used to advance the development of NorthSea Therapeutics’ pipeline of Structural Engineered Fatty Acids (SEFA) clinical-stage programs in NASH and other metabolic disorders. 

The company is currently working on three clinical-stage programs:

  • Icosabutate: NST’s lead product, which recently completed enrolment of its phase 2b ICONA study in NASH and reported strong interim results. Interim results showed reduction of biomarkers in liver injury, inflammation, and fibrosis in biopsy-confirmed NASH patients. In addition, treatment with Icosabutate showed a favourable safety and tolerability profile and additional improvements in atherogenic lipids and glycemic control. Preparations for entering phase 3 will begin next year, in anticipation of top-line results in Q1-2023
  • SEFA-1024: NST’s second SEFA programme, is in development for dyslipidemia. The phase 1 study is ongoing and is expected to be advanced to phase 2 in Q1-2023
  • SEFA-6179: Enters phase 1 trials this month for the orphan indication Intestinal Failure  Associated Liver Disease (IFALD). Funding is already secured for a phase 2 study scheduled to start by Q1-2023

What does NorthSea Therapeutics offer?

The company was founded in 2017 by David A. Fraser, Hilde H. Steineger, Patrick Round, Rob de Ree, and Tore Skjæret. It is a Dutch biotech company focused on developing structurally engineered fatty acids (‘SEFAs’) for the treatment of NASH and other metabolic disorders. 

NorthSea Therapeutics has licensed the rights to its lead compound icosabutate and a library of SEFAs from Pronova BioPharma Norge AS.

Icosabutate has been found safe and effective in two prior phase 2 clinical studies for treatment of hypertriglyceridemia and mixed dyslipidemia, and is currently in clinical development for NASH. The icosabutate phase 2b ICONA NASH trial is scheduled to readout in the first quarter of 2023. 

Two additional SEFAs are in clinical development – SEFA-1024 is in phase 1 to be developed for dyslipidemia, and SEFA-6179, which entered phase 1 this month, is being developed for the orphan indication IFALD, (Intestinal Failure Associated Liver Disease). 

Headquartered in Amsterdam, NST also has a presence in Norway and the US and is supported by investors including Ysios Capital, Forbion Growth, Hercules Capital, Forbion Ventures, Novo Seeds, BGV, NSV, venBio Partners, and Sofinnova investments.

 - Partner content -
How cybersecurity scaleup Intigriti conquered the world?
How cybersecurity scaleup Intigriti conquered the world?
Catch our interview with Paul Down, Head of Sales at Intigriti.
Catch our interview with Paul Down, Head of Sales at Intigriti. Show Less
Read more
Tags: amsterdamfeaturedfundingnews
Share2Tweet7SendShare10

Partner content | Work with us

Tokenisation is the future of the financial services industry, and Luxembourg’s Tokeny is at the helm of this change

Copilot for growers: Source.ag’s Rien Kamman explains how it helps growers increase their fresh produce with AI

Waste problem is complex, but Seenons has a solution: CEO and co-founder Joost Kamermans explains the plan

Want to scale your business in Germany and Europe? Here’s how the Scaleup Landing Pad Hamburg can help

Is your deep tech scaleup aiming high? The EIT Digital Challenge 2022 can get you there

Silicon Canals | Jobs


Breaking news from Amsterdam | Partner

Founders on funding: Greener Power Solutions’ founders on their effort to reduce CO2 footprint and raising funds to support it

Founder in Residence: Slimmer AI’s Daniela Redondo Vélez on how it aims to help founders early in their dream to build new age B2B AI solutions

Amsterdam and Paris-based Trezy bags €1M, opens European headquarters in the Dutch capital

Amsterdam’s Just Eat Takeaway made progress towards profitability in H1 2022: Report

Advertisement

  • About Silicon Canals
  • Partner with Silicon Canals
  • Contact us
  • Newsletter
  • Disclaimer
  • Privacy Policy
  • Cookie Policy (UK)
  • Cookie Policy (EU)
  • Terms & Conditions Silicon Canals

Silicon Canals 2014-2022 | Website: Bright Idiots

No Result
View All Result
  • Home
  • News
    • Ukraine
    • Startups
    • Scaleups
    • Coin Canals
    • FinTech
    • AI and chatbots
    • Travel & Mobility
    • Software & SaaS
    • Health & Medtech
    • (Crowd)funding
    • Blockchain
    • Internet of things
    • Hardware
    • Accelerators
    • E-commerce
    • Cybersecurity
    • Gaming & Virtual Reality
    • Drones
    • COVID-19
  • Features
    • How-to
    • Knowledge & Insights
    • Guest Contributions
  • Partners
    • Amsterdam
    • Rise by Techleap.nl
    • Fintech Files by AWS
    • Scaling-up in Europe
    • Blue Tulip Awards
    • Partner with us
    • Promoted content
  • Jobs
  • About us
    • Partner with us
    • About
    • Team
    • Newsletter
  • Contact

Silicon Canals 2014-2022 | Website: Bright Idiots

Stay updated with the Silicon Canals daily and weekly newsletters.
We promise we won't spam you. You can choose to unsubscribe anytime.
Stay updated with the Silicon Canals daily and weekly newsletters.
We promise we won't spam you. You can choose to unsubscribe anytime.
Silicon Canals
Manage your privacy

To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.

Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Statistics

Marketing

Features
Always active

Always active
Manage options Manage services Manage vendors Read more about these purposes
Manage options
{title} {title} {title}
X
X